HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $400 | -34.9% | 11,087 | -31.1% | 0.00% | -25.0% |
| Q1 2023 | $614 | -6.8% | 16,087 | +38.9% | 0.00% | -20.0% |
| Q4 2022 | $659 | -99.9% | 11,581 | -62.4% | 0.01% | -44.4% |
| Q3 2022 | $1,217,000 | -48.2% | 30,774 | -42.4% | 0.01% | -47.1% |
| Q2 2022 | $2,350,000 | +10.3% | 53,398 | 0.0% | 0.02% | +41.7% |
| Q1 2022 | $2,130,000 | -83.6% | 53,398 | -83.5% | 0.01% | -82.1% |
| Q4 2021 | $13,027,000 | -7.0% | 323,083 | -6.2% | 0.07% | -13.0% |
| Q3 2021 | $14,006,000 | +57.6% | 344,302 | +75.9% | 0.08% | +40.0% |
| Q2 2021 | $8,887,000 | +8.9% | 195,714 | 0.0% | 0.06% | +1.9% |
| Q1 2021 | $8,159,000 | +212.6% | 195,714 | +220.3% | 0.05% | +200.0% |
| Q4 2020 | $2,610,000 | +23.2% | 61,100 | -24.2% | 0.02% | +20.0% |
| Q3 2020 | $2,118,000 | +144.6% | 80,600 | +149.5% | 0.02% | +114.3% |
| Q2 2020 | $866,000 | – | 32,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |